Telmisartan, the active ingredient of Micardis, is an angiotensin II receptor blocker used for adult hypertension and cardiovascular risk reduction. It relaxes blood vessels by blocking AT1 receptors, helping lower arterial pressure and reduce strain on the heart.
Micardis is a brand-name antihypertensive containing telmisartan. Telmisartan belongs to the angiotensin II receptor blocker class, also called ARBs. It is prescribed for adults with essential hypertension, where blood pressure remains persistently elevated without a single identifiable cause.
Micardis may be prescribed for:
Micardis contains telmisartan as its active substance. Telmisartan belongs to the angiotensin II receptor blocker class and acts at AT1 receptors to reduce vasoconstriction.
The dose is decided individually, taking age, other medicines, and health conditions into account. Micardis is supplied as tablets for oral use.
| Formulation type | Active substance | Main pharmacological action |
|---|---|---|
| Micardis tablets | Telmisartan | AT1 receptor blockade and reduced vasoconstriction |
Telmisartan is an AT1 angiotensin II receptor antagonist. Angiotensin II normally binds to AT1 receptors in blood-vessel walls and other tissues. This promotes vasoconstriction, stimulates aldosterone release, encourages sodium retention, and increases blood pressure.
Telmisartan occupies these receptors and prevents angiotensin II from producing its usual constricting effect. The blood vessels remain more relaxed, systemic vascular resistance falls, and the heart pumps against less pressure. Aldosterone-driven sodium retention may also be reduced.
This action is selective. Telmisartan does not block the formation of angiotensin II directly, and it does not inhibit the breakdown of bradykinin in the same way as an ACE inhibitor. That pharmacological difference helps explain why cough is less characteristic with ARBs than with ACE inhibitors.
The antihypertensive effect develops through regular treatment rather than through a dramatic immediate sensation. A person may feel no different while the medicine lowers pressure and reduces cardiovascular workload.
The AT1 receptor pathway is also relevant to kidney protection and cardiovascular risk management, although the balance of benefit depends on the patient’s diagnosis, renal function, potassium level, and other treatments. The FDA prescribing information describes telmisartan as a selective angiotensin II receptor blocker with sustained blood-pressure activity [2].
Micardis is a brand-name antihypertensive containing telmisartan. It is prescribed for adults with essential hypertension, where blood pressure remains persistently elevated without a single identifiable cause.
The medicine may also be used in adults with increased cardiovascular risk when reducing blood pressure and blocking excessive angiotensin II activity form part of the risk-management plan. The European Medicines Agency describes telmisartan as an AT1 receptor antagonist that lowers vascular resistance and supports blood-pressure control [1].
Micardis may be prescribed for:
Several practical errors can reduce blood-pressure control or increase adverse effects:
Severe vomiting, diarrhoea, faintness, or inability to keep fluids down warrants prompt clinical advice because dehydration can worsen kidney stress.
Micardis may not be suitable if you have had a serious allergic reaction to telmisartan or one of the ingredients. It should not be used during the second or third trimester of pregnancy. Tell a clinician if you have severe kidney or liver problems, dehydration, high potassium, gout, diabetes, heart failure, or blood pressure that is already low.
Micardis is often tolerated without major problems, yet adverse effects remain possible. Dizziness, headache, tiredness, and low blood pressure can occur, especially when treatment begins, the dose changes, or fluid intake has been reduced.
The risk profile can change when hydrochlorothiazide is included. The diuretic component may contribute to dehydration, low sodium, low potassium, increased uric acid, or changes in glucose control. The FDA label and post-marketing safety information describe these clinically relevant reactions and monitoring needs [3].
Possible reactions to telmisartan include:
Dizziness is more likely after standing quickly, during fever, after vomiting or diarrhoea, or when another medicine also lowers blood pressure. Severe fainting, marked weakness, confusion, or an unusually low pulse requires prompt medical assessment.
Some patients notice more urination when hydrochlorothiazide is part of the treatment. This can be inconvenient during work or travel, especially if the tablet is taken late in the evening.
Hydrochlorothiazide may cause:
A patient taking a combination formulation may need blood tests for kidney function and electrolytes. Potassium supplements, salt substitutes containing potassium, and several medicines for heart failure or pain can alter the result.
A practical detail is easy to miss: thirst is not a reliable measure of hydration in older adults. Weakness, cramps, new confusion, or a sudden fall can appear before strong thirst develops.
Micardis is a single-ingredient oral treatment that lowers blood pressure by blocking AT1 receptors. This mechanism differs from approaches that reduce blood pressure through other pathways or combine multiple active substances.
In clinical practice, doctors usually judge Micardis by blood-pressure readings, kidney function, potassium levels, and cardiovascular risk rather than by whether the patient feels an immediate change.
A useful prescribing principle is to assess the whole regimen. If blood pressure remains high, the reason may be missed doses, excessive salt intake, NSAID use, untreated sleep apnoea, fluid retention, or an unsuitable combination of medicines. Increasing telmisartan without checking these factors can miss the real cause.
Clinicians also watch the first weeks after initiation or dose adjustment. Mild dizziness may settle as the body adapts, while persistent faintness may signal excessive blood-pressure reduction or dehydration. A sudden creatinine rise or potassium increase changes the treatment decision.
For patients taking hydrochlorothiazide, periodic electrolyte and uric-acid assessment may be appropriate. The need depends on age, kidney function, diabetes, gout history, fluid losses, and other medicines.
A history of serious allergy to telmisartan or a formulation ingredient rules out Micardis. Pregnancy after the first trimester is also a clear contraindication because renin–angiotensin system blockade can harm fetal kidney development. MHRA safety guidance available in 2025 continues to treat these warnings as clinically significant. A clinician may also avoid treatment in severe liver or kidney disease, depending on the circumstances.
Take the missed tablet when remembered unless the next dose is due soon. Skipping the missed dose is preferable to taking two doses together. NHS medicine guidance in 2024 supports avoiding a double dose for missed antihypertensive tablets, while the individual plan may differ when kidney function or other medicines are involved. Vomiting or diarrhoea should be mentioned because dehydration changes the safety assessment.
Lowering dietary salt, maintaining a healthy weight, exercising regularly, limiting excess alcohol, and avoiding tobacco support blood-pressure control. Large amounts of liquorice can raise blood pressure and may interfere with treatment, while dehydration from strenuous exercise, vomiting, or diarrhoea can increase dizziness and kidney stress. NICE hypertension guidance updated in 2023 recommends lifestyle measures alongside antihypertensive treatment rather than as a replacement for prescribed therapy. Home blood-pressure readings are more useful when taken under consistent conditions.
Yes. Dizziness or light-headedness can occur when blood pressure falls, especially after starting treatment, increasing the dose, standing quickly, or becoming dehydrated. Telmisartan may cause this effect, and hydrochlorothiazide can add to it by increasing fluid loss. The EMA product information published in 2024 describes hypotension-related symptoms as a recognised concern, while persistent fainting, confusion, or severe weakness requires urgent assessment. Checking blood pressure while symptoms occur can help guide the review.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
My readings became steadier after the first couple of weeks. I felt slightly light-headed after gym sessions at first, so I stopped checking pressure only when I felt well and started recording it properly.
The tablets were easy to fit into my routine, and I did not notice much day to day. The downside was a dry, tired feeling during the first week, which improved after my clinician reviewed my other blood-pressure tablets.
I expected to feel an obvious change, but there was no sensation at all. The home monitor showed improvement after several weeks. I had to stop taking doses at random times because my readings became difficult to compare.
The pressure readings improved, but morning urination became inconvenient when I took the pill late. Moving it earlier helped, although blood tests were needed after the change.
